User profiles for Pankti D Reid
 | Pankti D. Reid, MD MPHAssistant Professor, University of Chicago Verified email at uchospitals.edu Cited by 1716 |
COVIDOSE: a phase II clinical trial of low‐dose tocilizumab in the treatment of noncritical COVID‐19 pneumonia
Interleukin‐6 (IL‐6)–mediated hyperinflammation may contribute to the mortality of coronavirus
disease 2019 (COVID‐19). The IL‐6 receptor–blocking monoclonal antibody tocilizumab …
disease 2019 (COVID‐19). The IL‐6 receptor–blocking monoclonal antibody tocilizumab …
Management of immunotherapy-related toxicities in patients treated with immune checkpoint inhibitor therapy
of the Clinical Problem ICIs are monoclonal antibodies that block inhibitory regulatory proteins.
Their use leads to T-cell activation, engaging the immune system to treat the malignancy. …
Their use leads to T-cell activation, engaging the immune system to treat the malignancy. …
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis
AR Bass, N Abdel-Wahab, PD Reid… - Annals of the …, 2023 - ard.bmj.com
Objectives To compare the safety and effectiveness of biologic and conventional disease-modifying
antirheumatic drugs (DMARDs) for immune checkpoint inhibitor-associated …
antirheumatic drugs (DMARDs) for immune checkpoint inhibitor-associated …
COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19
Background Interleukin-6 (IL-6)-mediated hyperinflammation may contribute to the high
mortality of coronavirus disease 2019 (Covid-19). Tocilizumab, an IL-6 receptor blocking …
mortality of coronavirus disease 2019 (Covid-19). Tocilizumab, an IL-6 receptor blocking …
[HTML][HTML] Socially optimal pandemic drug dosing
Randomised controlled trials are essential to show a drug’s efficacy, but they ignore the
possibility that the drug under study might become too scarce to treat a population. Scarcity of life…
possibility that the drug under study might become too scarce to treat a population. Scarcity of life…
Applied clinical pharmacology in a crisis: Interleukin‐6 axis blockade and COVID‐19
GW Strohbehn, PD Reid… - Clinical Pharmacology & …, 2020 - Wiley Online Library
The global pandemic of coronavirus disease 2019 (COVID‐19) represents an emergent
threat to the public health. Mitigation strategies have been employed to varying effect in many …
threat to the public health. Mitigation strategies have been employed to varying effect in many …
Immune Checkpoint Inhibitor Therapy Toxicities—Reply
To the Editor A recent JAMA Clinical Guidelines Synopsis discussed the management of
immunotherapy-related toxicities in patients treated with immune checkpoint inhibitors, …
immunotherapy-related toxicities in patients treated with immune checkpoint inhibitors, …
COVIDOSE: Low-dose tocilizumab inthe treatment of COVID-19 pneumonitis
Background: Morbidity and mortality due to coronavirus disease 2019 (COVID-19) may in
part be due tointerleukin-6 (IL-6)-mediated hyperinflammation. The IL-6 receptor-targeted …
part be due tointerleukin-6 (IL-6)-mediated hyperinflammation. The IL-6 receptor-targeted …
Immune-Related Adverse Events from Cancer Immunotherapy
PD Reid, AR Bass - Clinical Innovation in Rheumatology, 2022 - api.taylorfrancis.com
Immune-related adverse events (irAEs) constitute a new autoimmune disease entity that
results from off-target toxicity after treatment with cancer immunotherapy. Immune checkpoint …
results from off-target toxicity after treatment with cancer immunotherapy. Immune checkpoint …
Abstract S05-02: COVIDOSE: Low-dose tocilizumab in the treatment of COVID-19 pneumonitis
Background: Morbidity and mortality due to coronavirus disease 2019 (COVID-19) may in
part be due to interleukin-6 (IL-6)-mediated hyperinflammation. The IL-6 receptor-targeted …
part be due to interleukin-6 (IL-6)-mediated hyperinflammation. The IL-6 receptor-targeted …